Most Read This Week
- Taselisib or Placebo With Fulvestrant in ER-Positive, PIK3CA-Mutant, HER2-Negative Advanced Breast Cancer
- Utidelone Plus Capecitabine vs Capecitabine for Heavily Pretreated, Anthracycline- and Taxane-Refractory Metastatic Breast Cancer
- Three Barriers to Improving Breast Cancer Outcomes in Sub-Saharan Africa
- Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination–Related Genes
- Dr. Farzanna Haffizulla: Making Time and Making That Time Count
Recently Updated
- Phase Ib Clinical Trial of Vantictumab + Paclitaxel in Patients With Locally Advanced or Metastatic HER2− Breast Cancer
- Sacituzumab Govitecan in Previously Treated Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer
- Efficacy of Intravenous NEPA for the Prevention of CINV During Cisplatin- and Anthracycline Cyclophosphamide–Based Chemotherapy
- Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2− Advanced Breast Cancer
- Taselisib or Placebo With Fulvestrant in ER-Positive, PIK3CA-Mutant, HER2-Negative Advanced Breast Cancer